Celltrion Keeps Pace With Ustekinumab Rivals

Moves CT-P43 Stelara Biosimilar Into Phase III Trials

 
• By Dave Wallace

Celltrion is looking to keep its ustekinumab biosimilar program in step with those of rival developers, after announcing the start of Phase III trials for its CT-P43 candidate.

Running Race Feet
Multiple players are in the race to develop a Stelara biosimilar • Source: Shutterstock

More from Biosimilars

More from Products